Polyclonal antibody stimulator(Aphton Corp.)(Polyclonal antibody stimulator(Aphton Corp.)) - 药物靶点：GAST_在研适应症：胰腺癌，胃癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、结合疫苗

别名

Anti-gastrin 17 immunogen、Antigastrin 17、Gastrimmune

+ [9]

靶点

GAST

作用方式

抑制剂、刺激剂

作用机制

GAST抑制剂(促胃泌素17抑制剂)、免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Cancer Advances, Inc.

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床试验

NCT00020787

/ Completed临床3期IIT

An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

开始日期2001-07-01

申办/合作机构

Jonsson Comprehensive Cancer Center

NCT02118077

/ Completed临床3期

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

开始日期2001-04-01

申办/合作机构

Cancer Advances, Inc.

NCT02118064

/ Completed临床2期

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

开始日期2001-03-01

申办/合作机构

Cancer Advances, Inc.

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的专利（医药）

登录后查看更多信息

2,715

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的文献（医药）

2025-10-01·Journal of Environmental Sciences

Developmental exposure to echimidine induces locomotor hyperactivity in zebrafish larvae via inhibiting acetylcholinesterase activity

Article

作者: Ren, Yingyi ; Luo, Zhiqiang ; He, Chengyong ; Lin, Tingting ; Chen, Siyu ; Yang, Jian ; Liang, Junyu ; Zuo, Zhenghong

Pyrrolizidine alkaloids (PAs) are natural toxins generated as secondary metabolites in plants, predominantly consisting of unsaturated PAs with diverse toxicities, such as hepatotoxicity. Echimidine, a prominent PA, is believed to exert various toxicological effects, including survival inhibition and induction of apoptosis of hepatocytes. However, the effects of echimidine on development remain unclear. We selected three concentrations of 0.02, 0.2, and 2 mg/L to investigate the developmental toxicity of echimidine on zebrafish embryos. After a 7-day exposure, we observed hyperactivity and anxiety-like behavior in zebrafish larvae. Furthermore, we found that echimidine exposure significantly promoted embryonic motor neurodevelopment in genetically modified zebrafish. Next, we detected that echimidine exposure significantly increased the content of the excitatory neurotransmitter acetylcholine (ACh), accompanied by a significant decrease in acetylcholinesterase (AChE) activity. Conversely, echimidine led to a significant reduction in the content of the sedative neurotransmitter γ-aminobutyric acid (GABA), accompanied by abnormal gene expression of enzymes related to GABA synthesis. Moreover, we elucidated the strong direct binding of echimidine to zebrafish and human AChE protein through molecular docking. In summary, our study found that echimidine induced ACh accumulation possibly by inhibiting AChE activity, leading to motor neurodevelopmental abnormalities and hyperactivity in zebrafish larvae. This work provides important scientific knowledge on the effects and mechanisms of PAs on neural development, which is helpful for controlling the risk of PAs in food and protecting public health.

2025-09-01·FOOD CHEMISTRY

Magnetic graphene oxide nanocomposite materials for magnetic dispersive solid-phase extraction and determination of pyrrolizidine alkaloids in tea beverages

Article

作者: Li, Shiqi ; Yi, Yuexing ; Huang, Xuchen ; Ma, Guicen ; Chen, Hongping ; Li, Zuguang ; Lu, Yuting

Pyrrolizidine alkaloids (PAs) and their N-oxides (PANOs) are plant-derived toxins, and tea beverages represent one of the most important exposure pathways of PAs/PANOs for human being. Therefore, establishing a method for the sensitive determination of PAs/PANOs is of great significance. In this study, magnetic graphene oxide (MGO) nanocomposite materials were used as an adsorbent in magnetic dispersive solid-phase extraction (d-MSPE) for quantifying PAs/PANOs in tea beverages. MGO exhibited high adsorption efficiency of PAs/PANOs from 83 % to 99 %, with rapid adsorption occurring within 20 min and desorption taking only 6 min. Under optimized conditions, the method showed excellent linearity (1-500 μg/L), low detection limits (0.01-0.6 μg/L), and good precision (RSD < 9.4 %). These results demonstrate the d-MSPE is a simple, efficient, and rapid method for the sample pretreatment and determination of PAs/PANOs in tea beverages.

2025-08-01·FOOD CHEMISTRY

Comprehensive review of pyrrolizidine alkaloids in bee products: Occurrence, extraction, and analytical methods

Review

作者: Gonzaga, Luciano Valdemiro ; Costa, Ana Carolina Oliveira ; Silva, Bibiana ; Brugnerotto, Patricia

Pyrrolizidine alkaloids (PAs) and their N-oxides (PANOs) are hepatotoxic secondary metabolites present in certain plant genera, raising health concerns due to their inevitable occurrence in bee products like honey, pollen, royal jelly, and propolis. The European Commission has set a 500 μg kg^-1 limit for PAs/PANOs in pollen-based supplements to ensure safety, emphasizing the need for sensitive analytical methods. This review, based on studies published between 2019 and 2024, identifies 51 compounds in bee products, including 32 PAs and 19 PANOs, with lycopsamine, senecionine, echimidine, intermedine, and retrorsine being the most studied. Solvent extraction, often combined with SPE or QuEChERS, is the most used preparation method, while liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is preferred for detection. Few studies assessed the risk of PAs consumption. These findings support regulatory monitoring of bee product safety and highlight the need for refining detection methods and establishing standardized limits and monitoring for PAs/PANOs.

1

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的新闻（医药）

2023-02-28

·BioSpace

Cancer Advances, Inc. Announces Issuance of New U.S. Patent - February 28, 2023

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers. The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination. “After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances. The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience. About Polyclonal Antibody Stimulator (PAS) Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program. Contact Cancer Advances, Inc. E-mail: jwingen@canceradvances.com

疫苗免疫疗法

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB04914

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃癌	临床3期	美国	Cancer Advances, Inc.	2009-01-19
胰腺腺癌	临床3期	-	Cancer Advances, Inc.	2000-08-14
胰腺癌	临床3期	-	Aphton Corp.	-
胃食管反流	临床2期	美国	Cancer Advances, Inc.	2009-01-20
食管癌	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃食管交界处恶性肿瘤	临床2期	-	Cancer Advances, Inc.	2000-08-01
黄疸	临床2期	-	Cancer Advances, Inc.	1999-08-01
胃腺癌	临床2期	-	Cancer Advances, Inc.	1998-09-01
大肠腺癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01
转移性结直肠癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床3期	胰腺癌	-	Gemcitabine + G17DT	壓鏇鹽願衊築範築鬱繭(蓋鑰觸鏇襯鑰糧觸積廠) = 築積壓鑰膚蓋範鑰範網繭糧積鑰鏇壓襯蓋齋製 (廠蓋糧積艱鑰窪鬱膚繭 )	-	2006-06-20
				Gemcitabine alone (placebo)	壓鏇鹽願衊築範築鬱繭(蓋鑰觸鏇襯鑰糧觸積廠) = 鬱鹹廠築積構糧網觸遞繭糧積鑰鏇壓襯蓋齋製 (廠蓋糧積艱鑰窪鬱膚繭 )
ASCO2004	N/A	不能切除性胰腺癌	154	G17DT	顧襯鑰築顧淵遞築製網(觸醖襯繭選夢蓋鬱簾鹹) = 製觸遞網簾糧膚選醖鏇鏇齋鹹積鏇餘鬱繭構顧 (醖顧淵願衊鹽製醖鹽艱 )	积极	2004-07-15
				Placebo	顧襯鑰築顧淵遞築製網(觸醖襯繭選夢蓋鬱簾鹹) = 鬱築網觸選構壓衊遞範鏇齋鹹積鏇餘鬱繭構顧 (醖顧淵願衊鹽製醖鹽艱 )